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Abstract 
The effect of chronically given morphine on the binding of ovine prolactin (oPRL) to specific areas in the male rat brain was studied. The drug 
was delivered through subcutaneously implanted miniosmotic pumps. The results indicated that the density of prolactin binding sites in the 
hypothalamus and the choroid plexus was significantly decreased in the acute phase of morphine administration but restored to control levels when 
tolerance to morphine was developed. The decrease in prolactin binding was contrasted by elevated plasma levels of the hormone. A negative 
correlation was found between the hormone concentration in plasma and the density of its binding sites in the hypothalamus and choroid plexus. 
The hormone-binding sites in these two regions were further characterized with regard to binding constants and molecular sizes. The relevance of 
the present results with respect o the hypothalamic ontrol of prolactin secretion is discussed. 
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1. Introduction 
The acute administration of opioid agonists elicits 
changes in the release of anterior pituitary hormones. 
Plasma levels of e.g. prolactin (PRL) and growth 
hormone (GH) are seen to increase in rodents, in non- 
human primates as well as in humans following acute 
opioid administrations [l-7]. Both morphine and p-en- 
dorphin, when injected (iv.) in adult male rhesus mon- 
keys, were found to produce immediate increases in 
PRL, which remained elevated for 3 h [g]. The stimula- 
tory effect of morphine was reversed by administration 
of the primarily p-opioid receptor antagonist naloxone. 
In male rats, intraventricular injections of morphine re- 
sulted in a significant increase of plasma PRL after 10 
min [9]. Studies have also shown that administration of 
morphine in the rat at a high dose (15 mg/kg s.c.) pro- 
duced at 4 h after administration suppressed plasma 
PRL concentrations [lo]. The authors concluded that 
morphine has a biphasic effect on the prolactin secretion. 
The neuroendocrine regulation of the PRL secretion 
is known to be a multi-factorial process, but dopamine 
(DA) secreted by the tuberoinfundibular dopaminergic 
neurons of the hypothalamus is believed to exert a pre- 
dominant tonic inhibitory control on the secretion of the 
hormone from the pituitary . In the hypothalamus PRL 
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receptors may mediate an action of the hormone on the 
DA-turnover [11,12]. It has also been shown that opioid 
agonists such as morphine or Met-enkephalin stimulate 
a naloxone-reversible PRL secretion from isolated ade- 
nohypophysial cells when they are co-incubated with hy- 
pothalamic fragments [13]. These findings support the 
hypothesis that one site of action of opioid compounds 
on pituitary PRL secretion is at the hypothalamic level 
. However, there are still several questions to be ad- 
dressed concerning the molecular mechanisms through 
which the opioids exert their effects and through which 
the hormone release is attenuated [lo] following pretreat- 
ment or chronic treatment with morphine. 
In this work we have directed studies on prolactin- 
binding in the male rat brain following chronic morphine 
administration. The drug was delivered by subcutane- 
ously implanted miniosmotic pumps and the PRL-bind- 
ing in different specific brain regions (including hypo- 
thalamus, striatum, cortex and choroid plexus) was 
determined at different stages of morphine dependence. 
The putative prolactin receptors were characterized with 
regard to binding constants and molecular sizes. 
2. Materials and methods 
2. I. Materials 
Male Sprague-Dawley (Alab, Sweden) rats weighing 240-260 g were 
housed in a room with controlled humidity (60%) and temperature 
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(23°C) and with fixed lighting schedule (light on from 8.00 h to 20.00 
h). Water and food were given ad libitum. The rats were adapted to the 
environment at least one week before the start of the experiment. One 
day before implantation of the pumps the animals were placed in indi- 
vidual cages with transparent walls and were kept there until the ending 
of the experiment. 
All rats were randomly divided into four groups each consisting of 
6 experimental and 6 control animals. Mini-osmotic pumps &let, 
2ML) were filled with morphine acetate (70 mg/ml) or saline and were 
implanted subcutaneously on the back under diethyl ether anaesthesia 
[ 14,15]. Experimental animals received morphine during varying time 
intervals. The first group (acute phase- or AP-group) was decapitated 
after 24 h following pump implantation. The second group (tolerance- 
or T-group) was decapitated after 120 h, just before pump removal. The 
third group (withdrawal- or W-group) was decapitated 20 hours after 
the pumps were removed (140 h after implantation). The fourth group 
(abstinence- or A- group) was decapitated 48 h after the pump removal 
or 168 h after the implantation. The development of tolerance and 
dependence was checked by determination of body weight, water con- 
sumption and pain sensitivity as described elsewhere [14,15]. 
2.2. Tissue dissection 
Following decapitation brain and liver were immediately removed 
and placed on ice. The brains were dissected on ice using a rat brain 
matrix (Activational Systems Inc., Morterra Drive Warren, Michigan, 
USA) as described previously [15]. The tissues collected were kept 
frozen at -80 “C until further processing. 
2.3. Preparation of receptor fractions 
The individual tissues were homogenized by ultrasonification for 5 
set at 0 “C in 25 mM Tris-HCI buffer pH 7.4, containing sucrose (lo%, 
w/v). The volumes were for choroid plexus and hypothalamus: 1ml/20 
mg; for cortex, hippocampus and striatum :2 ml/ibO mg; and for liver: 
5 ml/g. The homogenates were centrifuged at 9.000 x P for 10 min and 
the sipernatants were recentrifuged at-40,000 x g fo; 60 min at 4” C. 
The pellet fractions were collected and suspended in 25 mM Tris-HCl 
buffer, pH 7.4. All procedures were perfonned at 5°C or on ice and the 
suspensions were used immediately or stored at -80°C. 
2.4. Hormone labelling 
A highly purified preparation of oPRL (molecular mass (M,) 23,000, 
Sigma Chemical Company, St. Louis, MO, USA) was labelled with ‘251 
by the Chloramine T method. The specific activity of the labelled 
hormone was 145-160 ,&i/pg. 
2.5. Binding assays 
The assay for prolactin-binding to the receptor homogenates was 
conducted as described in a preceding paper [16]. Association constants 
and binding capacities were calculated [17] using the computer program 
LIGAND (Biosoft, Cambridge, UK). The analyses were based on ex- 
periments wherein [rZ51]oPRL was displaced by different amounts of 
unlabelled oPRL. Protein concentrations were determined according to 
Lowry et al. [IS]. 
2.6. Radioimmunoassay 
Plasma PRL was determined by radioimmunoassays (RIA) accord- 
ing to the procedure by Neil1 and Reichert [19] using a kit supplied by 
AIP (Amersham, UK) 
2.7. Covalent cross-linking of receptors to [‘tSI]oPRL 
Cross-linking of the iodinated hormone to receptor membranes was 
performed using disuccinimidyl suberate ( DSS, ICN Biomedicals, 
Planview, NY, USA ). Receptor homogenates (100 ,ul) were incubated 
overnight with [‘Z51]oPRL (60,000 cpm) at room temperature in a total 
volume of 250 ~1 PBS containing MgCI, (10 mM). Subsequently, 50 ~1 
of DSS (2.5 mM , freshly dissolved in dimethyl sulfoxide) was added 
and the tubes were kept at O’C for 15 min. The reaction was terminated 
by the addition of 15 ~12M Tris-HCI buffer, pH 7.4, containing 1 mM 
EDTA. Samples with an about 200-fold excess of unlabelled hormone 
were used as controls and run in parallel. 
2.8. SDS-electrtrophoresis of cross-linked complexes 
Following cross-linking, electrophoresis was performed in a discon- 
tinuous polyacrylamide gel as described in a preceding paper [16]. The 
samples (315 ~1) were mixed with a ‘sample cocktail’ (75 ~1 of 0.3 M 
Tris-HCl buffer pH 8.8 , containing 14% (w/v) sodium dodecyl sulphate 
(SDS), 10 mM dithiothreitol, 7.5 ~1 of 50% Trasylol (Fluka Chemika 
A.G., Switzerland), and 36% (w/v) sucrose) and boiled for 5 min. After 
alkvlation with 60 mM iodoacetamide for 15 min at 24”C, aliquots of 
40 ,& were electrophoresed for 45 min at 200 V using a Mini-Protean 
II apparatus (Bio-Rad Laboratories, Richmond, CA, USA). To locate 
the molecular weight markers the gels were stained with Coomassie 
brilliant blue R prior to autoradiography (Hypercassette, Amersham, 
UK). 
2.9. Statistical analysis 
The statistical analysis of data was performed by parametric or 
non-parametric one-way ANOVA and by using Student’s unpaired 
t-test. All calculations were carried out with the ‘Logstat’ program. 
3. Results 
Maximal analgetic effect of morphine was observed 
24 h following pump implantation. Analgesia was atten- 
uated after additional 24 h in spite of continuous delivery 
of morphine, that indicated the development of toler- 
ance. The sensitivity of experimental animals to pain 
remained at control levels until the pump was removed 
after 120 h . Twenty hours after removal of the pump, 
we observed the maximal expression of withdrawal signs 
(decreased body weight, decreased water consumption 
and hyperalgesia), which completely disappeared 48 h 
after pump removal, the abstinence state. All these ob- 
servations were thus in accordance with those described 
for this experimental animal model in a preceding paper 
1151. 
The binding of oPRL to choroid plexus and hypothal- 
amus was significantly reduced in morphine treated rats 
24 h after pump implantation (Table. 1, AP), i.e. in the 
acute phase. Following development of morphine toler- 
ance (Table.1, T) the density of PRL-binding was re- 
stored to control values in both tissues. During the state 
of withdrawal (W) an increase in PRL-binding was 
found in the hypothalamus, whereas a decrease was seen 
in the choroid plexus during the abstinence phase (A). 
No significant alteration was observed (Table 1) in the 
other tissues at the times studied. 
Data obtained by radioimmunoassays indicated a sig- 
nificant increase in plasma PRL at 24 h following pump 
implantation (morphine: 6.8 + 1.0 r&ml, control: 
3.4 + 0.45 r&ml; n = 6, P < 0.05). Furthermore, a nega- 
tive correlation was found between the plasma levels of 
the hormone and the density of its binding sites in the 
choroid plexus and the hypothalamus (Fig. 1). 
In order to exclude that the decreased binding simply 
resulted from masked receptors formed by elevated pro- 
lactin levels, additional experiments were performed. 
Thus, prior to binding experiments, the receptor prepa- 
rations were desaturated with 4 M MgCl, according to 
Kelly et al. [20]. The result indicated that this treatment 
slightly increased the binding in the liver but the effect 
on the brain tissue was negligible. The significant reduc- 
tion in the PRL binding observed in choroid plexus and 
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Fig. 1. Plasma levels of rat PRL plotted versus density of PRL binding 
sites in (A) hypothalamus and (B) choroid plexus from morphine 
treated rats. Tissues and plasma samples were collected at 24 h follow- 
ing pump implantation. The correlation between the hormone level and 
the specific PRL binding is significantly negative (A, plasma-hypothal- 
amus: J’ = -0.15x + 13.4, r2 = 0.658, P < 0.05; B, plasma-choroid 
plexus: _v = -0.52~ + 16.4, r2 = 0.812, P < 0.05). 
hypothalamus from morphine treated animals at 24 h 
(Table 1) remained also in receptor preparations desatu- 
rated with MgCl,. 
The most pronounced alteration in prolactin binding 
was thus observed in choroid plexus and hypothalamus 
24 h after implantation of the morphine pumps. These 
tissues were also found to exhibit the highest content of 
PRL-binding sites (Table 1). To further characterize the 
nature of these changes individual tissue samples col- 
lected from hypothalamus and choroid plexus 24 h after 
pump implantation (AP-group) were pooled. The bind- 
ing sites in both hypothalamus and choroid plexus were 
found to be saturable as well as dependent on pH and 
temperature. Calculation of affinity constants yielded 
values within the nanomolar range (Table 2), which did 
not differ in control and experimental animals, whereas 
the binding capacities were significantly lower for tissue 
pools obtained from morphine treated animals than for 
pools from control animals. 
The results of analytical electrophoresis of cross- 
linked hormone-receptor complexes (receptor material 
originating from choroid plexus and hypothalamus) in- 
dicated the presence of only one specific binding entity 
for prolactin (Fig. 2). The complex from each tissue was 
visualized as a single band corresponding to a protein of 
M, 59,000 (choroid plexus) and 60,000 (hypothalamus). 
After subtraction of M, 23,000 for oPRL these values are 
consistent with IV, values of 36,000 and 37,000 for the 
respective binding unit. 
It could further be seen in Fig. 2 that the density of the 
bands corresponding to hormone-receptor complexes 
obtained from morphine-treated animals (AP-group) 
were significantly reduced (lanes C and G), which is in 
accordance with the result shown in Table 1. 
4. Discussion 
In this study we have examined prolactin sites in dif- 
ferent regions of rat brain and liver following exposure 
to morphine. Only a few studies dealing with PRL bind- 
ing to discrete areas in the rat brain have been published 
(e.g. [21]). To our knowledge this is the first study report- 
Table 1 
Specific binding of [‘251]-oPRL to membranes from rat brain and liver 
.~ 
Tissue 
- 
Specific binding of “%oPRL per mg protein (s/o) 
AP (group) T (group) W (group) A (group) 
C M C M C M C M 
Choroid plexus 228 f 31 123 f 14** 217 + 20 200 f 79 206 f 6 210 + 42 227 f 23 lS9+26* 
Cortex 5.5 + 1.9 3.8 _+ 2.3 5.4 + 1.8 4.74 + 2.8 5.3 f 1.2 5.9 + 2.3 5.5 _+ 1.8 3.9 f 2.0 
Hippocampus 12.3 + 2.5 10.4 f 2.6 12.1 + 2.5 12.3 f 3.1 12.7 f 6 14.2 i: 6.8 12.2 f 5.4 9.9 + 3.3 
Hypothalamus 69.3 f 3.9 32 f 13** 65 f 11.2 62 + 9.5 67 f 1.0 81 f 2.6* 62 f 8.9 61 + 8.0 
Striatum 10.3 + 4.1 5.1 + 2.2 11.0 f 5.1 10.1 f 8.6 9.7 f 2.4 7.5 4 3.2 9.7 _+ 4.5 7.4 f 2.0 
Liver 11.3 f 3.0 13.0 f 2.6 10.5 + 2.0 9.6 f 1.7 10.2 f 4.1 7.7 + 3.0 10.8 f 2.6 7.5 + 3.4 
The values are means f SD. (n = 6). AP, Acute phase; T, Tolerance; W, Withdrawal; A, Abstinence; C, Control; M, Morphine. Stat&al evaluation 
was done with ANOVA (analysis of variance) and Student’s unpaired t-test (*P < 0.05, **P < 0.01). The alterations een in choroid plexus and 
hypothalamus were significant both with ANOVA and Student’s t-test. The protein concentrations were for Choroid Plexus: 0.748 (mg/ml); for Cortex: 
8.49 (mg/ml); for Hippocampus: 3.57 (mg/ml); for Hypothalamus: 2.02 (mg/ml); for Striatum: 2.79 (mg/ml); and for Liver: 13.8 (mg/ml). 
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Fig. 2. SDS-electrophoresis of cross-linked hormone-receptor com- 
plexes. Membrane-bound receptors from rat hypothalamus (A-D) and 
choroid plexus (E-H) were incubated and subsequently covalently 
cross-linked to [“‘I]oPRL (70,000 cpm) by disuccinimidyl suberate and 
ahquots of the complexes formed were subjected to SDS electrophoresis 
and autoradiography. Receptors from control groups (lanes D and H) 
indicate marked bands, whereas those from the acute phase of mor- 
phine treatment (C and G) appear as very weak bands. Samples applied 
in lanes A, B and E, F were prior to cross-linking incubated both with 
labelled and an excess of unlabelled hormone. The positions of molec- 
ular weight markers (molecular mass x10-‘) are indicated in the right 
margin. 
ing binding constants and molecular sizes of putative 
PRL receptors in rat brain regions as hypothalamus and 
choroid plexus. 
The estimated M, values for the PRL-binding units in 
hypothalamus and choroid plexus are somewhat lower 
than those found for the hormone in peripheral tissues 
of the rat. For instance, with the same experimental tech- 
nique M, values of 42,00044,000 have been reported for 
the rat liver receptor [22]. Recent studies have shown that 
two forms of PRL-receptor mRNA are detectable in the 
rat hypothalamus [23]. The predicted M,-values for the 
receptor proteins from these mRNA sequences were pre- 
viously reported to be 33,000 [24] and 67,000 [25] when 
studied in the rat liver. However, these values are calcu- 
lated from predicted amino acid sequences which do not 
include glycosylation. The observed size heterogeneity 
arose from alternative splicing of the same primary re- 
ceptor mRNA transcript [26]. 
The salient new finding reported here is the significant 
decrease in PRL-binding observed in the acute phase of 
morphine administration, i.e. 24 h after pump implanta- 
tion. At this time the maximal analgesic effect of mor- 
phine was observed prior to development of tolerance. 
The decrease in PRL-binding sites in the acute phase 
could reflect a down-regulation caused by a morphine- 
induced increase of the hormone secretion. The drug 
may act on the dopamine system in hypothalamus and 
thereby interfere with the mechanism controlling the 
PRL release [27]. However, the morphine-induced in- 
crease in PRL secretion was seen only during the acute 
phase of drug administration [8,9]. Studies have shown 
that continuous infusion of PRL in the rat from im- 
planted miniosmotic pumps does not affect the receptor 
content in peripheral tissues, such as the liver [28]. 
On the other hand, it can not be excluded that mor- 
phine has a direct effect on the PRL receptors in certain 
brain areas as hypothalamus and choroid plexus. Mor- 
phine may affect the expression of the receptor at the 
transcriptional evel. Chronic administration of opioid 
agonists have previously been shown to produce altera- 
tions in the gene transcript for several prepropeptides 
and also for peptide receptors. For instance, morphine 
was found to down-regulate the expression of 
proopiomelanocortin in the rat [29]. A similar observa- 
tion was made for the prodynorphin gene in the rat brain 
[30]. A down-regulation of the adenosine receptor activ- 
ity following morphine treatment was also reported [3 11. 
The molecular mechanism behind these alterations are, 
however, still unclear and needs further elucidation. 
The down-regulation of PRL receptors in the hypo- 
thalamus, as indicated by this study, is of importance for 
the control mechanism of the PRL secretion. A decrease 
in transduction of the PRL signal in this area will cer- 
tainly affect the activity in the DA neurons [12], leading 
to an increase in the secretion of the hormone from the 
anterior pituitary. It is therefore tempting to speculate 
whether the previously described enhancement in PRL 
secretion following administration of opioid agonists [l- 
93 may result from a direct effect on PRL receptors at the 
hypothalamic level. This would be in agreement with the 
negative correlation between the plasma level of the 
hormone and the density of its receptors in hypothala- 
mus as observed in this study. 
The reduction of PRL-binding sites in the choroid 
plexus may have consequences for the passage of the 
hormone over the blood-brain barrier according to a 
previously described hypothesis. The PRL binding-sites 
in this region were suggested to mediate the transport of 
PRL from the vascular compartment into the CNS 
[32,33]. Thus, a down-regulation of PRL receptors in 
choroid plexus in the acute phase may reduce the CNS 
Table 2 
Association constants (K,) and binding capacities for [‘*‘I]-oPRL to 
male rat membranes from choroid plexus and hypothalamus collected 
from animals in the acute phase of morphine treatment (24h following 
pump implantation) 
Tissue Binding capacity K, (nmol-‘) M, for oPRL- 
(nmol/mg protein) -binding unit 
Choroid plexus 
Control 1.96 * 0.10 2.2 + 0.9 
Morphine 0.62 + 0.02** 2.6 f 0.5 
36 000 f 1100 
Hypothalamus 
Control 0.71 f 0.05 4.5 * 1.2 
Morphine 0.45 + 0.06* 5.1 f 1.8 
37 000 + 1000 
Values are given as means + S.D. (n = 3). 
*P < 0.05, **p < 0.01. 
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levels of the hormone at this stage of chronic morphine 
administration. 
In conclusion, this work shows that prolactin-binding 
in hypothalamus and choroid plexus is significantly re- 
duced in the acute phase of morphine dependence. At 
this stage the density of the PRL-binding sites in these 
brain regions correlated negatively to the plasma levles 
of the hormone. The significance of these changes in 
relation to the effects of morphine at this stage of its 
administration is not yet clear. Alterations in the PRL- 
binding seen during withdrawal and abstinence (Table 1) 
suggest an involvment of PRL receptors in the expres- 
sion of both these states during the development of mor- 
phine dependence 
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